Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.

Abstract

Nowadays the dual antiplatelet therapy (DAPT) becomes more widely used in patients with ischemic stroke. Nevertheless, controversies exist for indications of DAPT. In view of evidence-based medicine analysis, patients with high-risk transient ischemic attack and minor stroke, severe symptomatic intracranial artery stenosis, symptomatic intracranial and extracranial artery stenosis causing artery-to-artery embolism, ischemic stroke attributed to aortic arch plaques, high-risk atrial fibrillation not suitable for oral anticoagulants, intracranial and extracranial stent implantation, and ischemic stroke with acute coronary syndrome may gain great benefit from DAPT of clopidogrel and aspirin. In clinical practice, individualized antiplatelet therapy strategies should be taken by weighing risks of ischemia and hemorrhage.

• Authors: Ya Su, Xin Cheng, Qiang Dong
• Journal: CNS neuroscience & therapeutics (CNS Neurosci Ther) Vol. 21 Issue 11 Pg. 870-6 (Nov 2015) ISSN: 1755-5949 [Electronic] England
• PMID: 26122554 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2015 John Wiley & Sons Ltd.

Chemical References

• Antiplatyhelmintic Agents
• Clopidogrel
• Ticlopidine
• Aspirin

Topics

• Antiplatyhelmintic Agents (therapeutic use)
• Aspirin (therapeutic use)
• Brain Ischemia (complications)
• Clopidogrel
• Evidence-Based Medicine
• Humans
• Stroke (etiology, prevention & control)
• Ticlopidine (analogs & derivatives, therapeutic use)